Federal Health Minister adds Neffy nasal spray to benefits scheme for Australians
Federal Health Minister Mark Butler announced the addition of Neffy, the first adrenaline nasal spray for anaphylaxis, to the Pharmaceutical Benefits Scheme, benefiting about 150,000 Australians. Patients will pay $25 per dose, providing an alternative to EpiPens. However, rising drug costs and delayed access to treatments continue to pressure the system, with some critically ill Australians still underserved.
Take it further — get the full app and never miss a moment of what's happening in Australia.
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
Published 29 Jun 2026, 13:10 UTC · Updated 29 Jun 2026, 13:20 UTC
Summary by OZbrief Editorial. Original report: 7 News. Editorial policy · Corrections
Trending
- Breaking: Australian arrested after teenage girl's body found in Thailand
- Court returns proceeds of house sale seized from convicted paedophile
- David Hencke, journalist who exposed 'cash for questions' scandal, dies at 79
- Paul Hogan has reportedly called Pauline Hanson a ‘pelican’. Please explain?
- Former CFMEU chief pleads for drug trafficker tied to Big Build corruption
- Austrian Grand Prix: Formula One qualifying – live